Possible multiple myeloma dedifferentiation following thalidomide therapy: A report of four cases

Leukemia and Lymphoma

Volumn 45, Issue 4, 2004, Pages 735-738

  Balleari, Enrico ^a   Ghio, Riccardo ^a   Falcone, Antonietta ^b   Musto, Pellegrino ^b  

^a UNIVERSITY OF GENOA   (Italy)

^b CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

Author keywords

Dedifferentiation; Extramedullary plasmacytoma; M component; Multiple myeloma; Plasmacells; Thalidomide

Indexed keywords

ALPHA INTERFERON; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; M PROTEIN; MELPHALAN; MITOXANTRONE; PREDNISONE; THALIDOMIDE; VINCRISTINE;

ADULT; AGED; ARTICLE; BONE MARROW BIOPSY; BONE MARROW DISEASE; BONE MARROW TOXICITY; CANCER GROWTH; CASE REPORT; DISEASE EXACERBATION; DRUG WITHDRAWAL; FEMALE; HUMAN; HUMAN TISSUE; MALE; MULTIPLE MYELOMA; MYELOMA CELL; OUTCOMES RESEARCH; PLASMACYTOSIS; PRIORITY JOURNAL; TUMOR DIFFERENTIATION;

AGED; AGED, 80 AND OVER; CELL DIFFERENTIATION; DISEASE PROGRESSION; FATAL OUTCOME; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; MYELOMA PROTEINS; THALIDOMIDE; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 1342266174     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.1080/10428190310001617231     Document Type: Article

References (20)

1. Tosi, P. and Cave, M. (2002) "Thalidomide in multiple myeloma: state of art", Haematologica, 87, 233-235.
2. Anderson, K.C. (2001) "Novel biologically based therapies for myeloma", Cancer Journal, 13(Suppl), 19-23.
3. Singhal, S., Metha, J., Desikan, R., Ayers, D., Roberson, P., Eddlemon, P., et al. (1999) "Antitumor activity of thalidomide in refractory multiple myeloma", New, England Journal of Medicine, 341, 1565-1571.
4. Kneller, A., Raanani, P., Hardan, I., Avigor, A., Levi, I., Berkowicz, M., et al. (2000) "Therapy with thalidomide in refractory multiple myeloma patients - the revival of an old drug", British Journal of Haematology, 108, 391-393.
5. Juliusson, G., Celsing, F., Turesson, I., Lenhoff, S., Adriansson, M. and Malm, C. (2000) "Frequent good partial remissions from thalidomide including best response ever in patients with advanced refractory and relapsed myeloma", British Journal of Haematology, 109, 89-96.
6. Pini, M., Baraldi, A., Pietrasanta, D., Allione, B., Depaoli, L., Salvi, F., et al. (2000) "Low-dose of thalidomide in the treatment of refractory myeloma", Haematologica, 85, 111-112.
7. Hus, M., Dmoszynska, A., Soroka-Woitaszko, M., Jawniak, D., Legiec, W., Ciepnuch, H., et al. (2001) "Thalidomide treatment of resistant or relapsed multiple myeloma patients". Haematologica, 86, 404-408.
8. Tosi, P., Ronconi, S., Zamagni, E., Cellini, C., Grafone, T., Cangini, D., et al. (2001) "Salvage therapy with thalidomide in multiple myeloma patients relapsing after autologous peripheral blood stem cell transplantation", Haematologica, 86, 409-413.
9. Tosi, P., Zamagni, E., Cellini, C., Ronconi, S., Patriarca, F., Ballerini, F., et al. (2002) "Salvage therapy with thalidomide in patients with advanced relapsed/refractory multiple myeloma", Haematologica, 87, 408-414.
10. Singhal, S. and Metha, J. (2001) "Thalidomide in cancer: potential use and limitations", Biodrugs, 15, 163-172.
11. Marriot, J.B., Muller, G. and Dalgleish, A.G. (1999) "Thalidomide as an emerging immunotherapeutic agent", Immunology Today, 20, 538-543.
12. D'Amato, R.J., Loughnan, M.S., Flynn, E. and Folkman, J. (1994) "Thalidomide is an inhibitor of angiogenesis", Proceedings of National Academy of Sciences USA, 91, 4082-4085.
13. Haslett, P.A., Corral, L.G., Albert, M. and Kaplan, G. (1998) "Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production and cytotoxic responses in the CD8 + subset", Journal of Experimental Medicine, 187, 1885-1892.
14. Davies, F.E., Raje, N., Hideshima, T., Lentzsch, S., Young, G., Tai, Y.T., et al. (2001) "Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma", Blood, 98, 210-216.
15. Sampaio, E.P., Sarno, E.N., Galilly, R., Cohn, Z.A. and Kaplan, G. (1991) "Thalidomide selectively inhibits tumor necrosis factor α production by stimulated human monocytes", Journal of Experimental Medicine, 173, 699-703.
16. Petrucci, M.T., Ricciardi, M.R. and Gregorj, C. (2000) "Thalidomide effects on apoptosis in multiple myeloma: ex vivo and in vitro study", Blood, 96(Suppl 1), 366 [abstract].
17. Pope, B., Brown, R.D., Gibson, J., Petersen, A., Wiley, J. and Joshua, D.E. (1997) "The functional phenotype of the primitive plasma cell in patients with multiple myeloma correlates with the clinical state", Leukemia and Lymphoma, 117, 83-91.
18. Sanal, S.M., Yaylaci, M., Mangold, K.A. and Pamazis, C.G. (1996) "Extensive extramedullary disease in myeloma. An uncommon variant with features of poor prognosis and dedifferantion", Cancer, 77, 1298-1302.
19. Avigdor, A., Raanani, P., Levi, I., Hardan, I. and Ben-Bassat, I. (2001) "Extramedullary progression despite a good response in the bone marrow in patients treated with thalidomide for multiple myeloma", Leukemia and Lymphoma, 42, 683-687.
20. Alegre, A., Granda, A., Martinez-Chamorro, C., Diaz-Mediavilla, J., Martinez, R., Garcia-Larana, J., et al. (2002) "Different patterns of relapse after peripheral blood stem cell transplantation in multiple myeloma: clinical results of 280 cases from the Spanish Registry", Haematologica, 87, 609-614.